Related Experiment Videos
One-year analysis of the iStent trabecular microbypass in secondary glaucoma
Oscar Buchacra1, Susana Duch, Elena Milla
1Department of Ophthalmology, Instituto Condal de Oftalmología, Barcelona, Spain.
Clinical Ophthalmology (Auckland, N.Z.)
|April 7, 2011
Summary
The iStent significantly lowered intraocular pressure and reduced medication needs in patients with secondary open-angle glaucoma over 12 months. This micro-invasive glaucoma surgery offers a safe and effective treatment option for managing complex glaucoma cases.
Area of Science:
- Ophthalmology
- Glaucoma Research
- Surgical Innovation
Background:
- Secondary open-angle glaucoma presents unique challenges in intraocular pressure (IOP) management.
- Evaluating novel micro-invasive glaucoma surgical (MIGS) devices is crucial for improving patient outcomes.
- The iStent, a suprachoroidal micro-bypass device, aims to reduce IOP by enhancing aqueous humor outflow.
Observation:
- A prospective case series evaluated 10 patients with secondary open-angle glaucoma undergoing iStent implantation.
- Patients were monitored for IOP, medication use, visual acuity, and complications up to 12 months post-procedure.
- Key metrics included Goldmann tonometry for IOP and medication counts.
Findings:
- Mean baseline IOP of 26.5 mmHg significantly decreased by 10.4 mmHg at 3 months, 7.4 mmHg at 6 months, and 6.6 mmHg at 12 months (P < 0.05).
- The average number of glaucoma medications reduced from 2.9 to approximately 1.8 at 3, 6, and 12 months (P < 0.05).
- Mild hyphema and transient IOP elevation were the most common complications, with spontaneous resolution; no significant visual acuity changes were noted.
Implications:
- The iStent demonstrates midterm efficacy and safety as a treatment for secondary open-angle glaucoma.
- This MIGS device effectively reduces IOP and the need for topical hypotensive medications.
- The iStent offers a valuable, less invasive surgical option for patients with complex glaucoma, potentially reducing treatment burden.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...